Cello Health (CLL)

Sector:

Health Care

Index:

FTSE AIM All-Share

   Trade now with Barclays Stockbrokers   Trade now with Barclays   Sponsored by Barclays Stockbrokers

128.00p
   
  • Change Today:
    -0.50p
  • 52 Week High: 139.50p
  • 52 Week Low: 96.00p
  • Currency: UK Pounds
  • Shares Issued: 104.77m
  • Volume: 1,546
  • Market Cap: £134.11m
  • RiskGrade: 90
  • Beta: 0.04

Cello Health revenues and headline profits grow in Q1

By Iain Gilbert

Date: Wednesday 08 May 2019

LONDON (ShareCast) - (Sharecast News) - Healthcare-focused advisory group Cello Health saw like-for-like net revenue and headline pre-tax profits grow in the first quarter of its trading year, something it expects to carry over into the second quarter.
Chairman Chris Jones told investors at the group's annual general meeting on Wednesday that Cello had seen "a very good start to the year" and was confident of its second-quarter outlook.

At a segment operating level, Jones revealed Cello had also had an "excellent first quarter". In particular, the AIM-listed firm's chair said performances in its consulting businesses and in the US overall were "notable".

"The board is therefore confident of achieving a successful full year result in 2019, in line with expectations," said Jones.

Cello also said the group's balance sheet remained strong, with better than expected cash conversion so far in 2019, continuing "the strong cash conversion performance" delivered in 2018. He also noted the group was continuing to assess "suitable acquisitive growth opportunities" in the US.

As of 1035 BST, Cello shares had picked up 1% to 133.32p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Cello Health Market Data

Currency UK Pounds
Share Price 128.00p
Change Today -0.50p
% Change -0.39 %
52 Week High 139.50p
52 Week Low 96.00p
Volume 1,546
Shares Issued 104.77m
Market Cap £134.11m
Beta 0.04
RiskGrade 90

Cello Health Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
58.11% below the market average58.11% below the market average58.11% below the market average58.11% below the market average58.11% below the market average
71.43% above the sector average71.43% above the sector average71.43% above the sector average71.43% above the sector average71.43% above the sector average
Price Trend
40.77% above the market average40.77% above the market average40.77% above the market average40.77% above the market average40.77% above the market average
33.33% above the sector average33.33% above the sector average33.33% above the sector average33.33% above the sector average33.33% above the sector average
Income
26.54% below the market average26.54% below the market average26.54% below the market average26.54% below the market average26.54% below the market average
38.46% above the sector average38.46% above the sector average38.46% above the sector average38.46% above the sector average38.46% above the sector average
Growth
31.09% below the market average31.09% below the market average31.09% below the market average31.09% below the market average31.09% below the market average
21.21% below the sector average21.21% below the sector average21.21% below the sector average21.21% below the sector average21.21% below the sector average

What The Brokers Say

Strong Buy 2
Buy 0
Neutral 0
Sell 0
Strong Sell 0
Total 2
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Cello Health Dividends

  Latest Previous
  Final Interim
Ex-Div 25-Apr-19 04-Oct-18
Paid 24-May-19 02-Nov-18
Amount 2.75p 1.10p

Trades for 18-Jun-2019

Time Volume / Share Price
12:12 1,546 @ 129.00p

Cello Health Key Personnel

CEO Mark Scott

Top of Page